Management of Fibromyalgia Syndrome: Review of Evidence
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Fibromyalgia syndrome (FMS) is a common chronic musculoskeletal pain disorder of unknown etiology and characterized by generalized body pain, hyperalgesia, and other functional and emotional comorbidities. Despite extensive research, no treatment modality is effective for all FMS patients. In this paper, we briefly review the history of FMS and diagnostic criteria, and potential pathophysiological mechanisms including central pain modulation, neurotransmitters, sympatho-adrenal and hypothalamic-pituitary-adrenal systems and peripheral muscle issues. The primary focus of the paper is to review treatment options for managing fibromyalgia symptoms. We will discuss FDA-approved medications and other pharmacologic agents, and non-pharmacologic treatments that have shown promising effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central sensitization: implications for the diagnosis and treatment of pain
Woolf, C. J. (2011) · Pain · doi:10.1016/j.pain.2010.09.030 · Cited by 4,771
Wolfe, F., Clauw, D. J., Fitzcharles, M., Goldenberg, D. L., Katz, R. S., Mease, P., Russell, A. S., Russell, I. J., Winfield, J. B., & Yunus, M. B. (2010) · Arthritis Care & Research · doi:10.1002/acr.20140 · Cited by 3,952 · cited 1×
“In order to address these concerns, new diagnostic criteria for FMS were proposed recently, based on data from another multicenter study [17].”
BackgroundFunctional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia
Gracely, R. H., Petzke, F., Wolf, J. M., & Clauw, D. J. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10225 · Cited by 1,263 · cited 1×
“Cortical activities in response to noxious stimulation are exaggerated in patients with FMS [19, 23, 24].”
BackgroundPrimary fibromyalgia (fibrositis): Clinical study of 50 patients with matched normal controls
Yunus, M., Masi, A. T., Calabro, J. J., Miller, K. A., & Feigenbaum, S. L. (1981) · Seminars in Arthritis and Rheumatism · doi:10.1016/0049-0172(81)90096-2 · Cited by 910 · cited 1×
“The assumption persisted until systematic scientific studies began to appear in the literature in the 1970s, when an underlying inflammation was ruled out and a more neutral term fibromyalgia proposed [6, 7].”
BackgroundArnold, L. M., Lu, Y., Crofford, L. J., Wohlreich, M., Detke, M. J., Iyengar, S., & Goldstein, D. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20485 · Cited by 624 · cited 1×
“Double-blind RCTs evaluating duloxetine doses ranging between 60 and 120 mg per day have typically shown greater improvement in pain reports and self-report functioning than those in the placebo arm [60–62].”
BackgroundMultidisciplinary treatment for chronic pain: a systematic review of interventions and outcomes
Scascighini, L., Toma, V., Dober-Spielmann, S., & Sprott, H. (2008) · Rheumatology · doi:10.1093/rheumatology/ken021 · Cited by 613 · cited 1×
“A systematic review [116] points to the methodological weakness, yet provides some evidence of the effectiveness of the approach for various”
BackgroundHypothalamic–pituitary–adrenal axis perturbations in patients with fibromyalgia
Crofford, L. J., Pillemer, S. R., Kalogeras, K. T., Cash, J. M., Michelson, D., Kling, M. A., Sternberg, E. M., Gold, P. W., Chrousos, G. P., & Wilder, R. L. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780371105 · Cited by 508 · cited 1×
“associated with altered basal catecholamine levels, independent of depression [33, 34], as well as abnormal reactivity of the HPA, such as abnormal adrenocorticotropic hormone (ACTH) levels, hypoglycemia and blunted cortisol response [35, 36].”
BackgroundGrossman, P., Tiefenthaler-Gilmer, U., Raysz, A., & Kesper, U. (2007) · Psychotherapy and Psychosomatics · doi:10.1159/000101501 · Cited by 505
Arnold, L. M., Rosen, A., Pritchett, Y. L., D'Souza, D. N., Goldstein, D. J., Iyengar, S., & Wernicke, J. F. (2005) · Pain · doi:10.1016/j.pain.2005.06.031 · Cited by 471 · cited 1×
“1 Percentage of patients reporting [30% pain reduction by dose for pregabalin [56], duloxetine [60], and milnacipran [69] versus placebo.”
BackgroundBennett, R. M., Kamin, M., Karim, R., & Rosenthal, N. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00116-5 · Cited by 403
Cannabinoids for treatment of chronic non‐cancer pain; a systematic review of randomized trials
Lynch, M. E., & Campbell, F. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03970.x · Cited by 397 · cited 1×
“A systematic review of cannabinoids for treating non-cancer chronic pain [103] suggests that they are safe and may have some modest benefit for FMS, although the results are very preliminary at this point.”
BackgroundNabilone for the treatment of pain in fibromyalgia.
Skrabek, R. Q., Galimova, L., Ethans, K., & Perry, D. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.002 · Cited by 384 · cited 1×
“In the first double-blind RCT [101], 40 FMS patients received either placebo or nabilone (titrated to 1 mg twice daily) for 4 weeks.”
Russell, J. I., Mease, P. J., Smith, T. R., Kajdasz, D. K., Wohlreich, M. M., Detke, M. J., Walker, D. J., Chappell, A. S., & Arnold, L. M. (2008) · Pain · doi:10.1016/j.pain.2008.02.024 · Cited by 367
The Effects of Nabilone on Sleep in Fibromyalgia: Results of a Randomized Controlled Trial
Ware, M. A., Fitzcharles, M.-A., Joseph, L., & Shir, Y. (2010) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181c76f70 · Cited by 324 · cited 1×
“[102] compared nabilone to amitriptyline in a crossover trial where patients received a 2-week trial of each drug with a 2-week washout in between.”
MethodGibson, S. J., Littlejohn, G. O., Gorman, M. M., Helme, R. D., & Granges, G. (1994) · Pain · doi:10.1016/0304-3959(94)90198-8 · Cited by 306 · cited 1×
“Cortical activities in response to noxious stimulation are exaggerated in patients with FMS [19, 23, 24].”
BackgroundSchmidt, S., Grossman, P., Schwarzer, B., Jena, S., Naumann, J., & Walach, H. (2011) · PAIN · doi:10.1016/j.pain.2010.10.043 · Cited by 297 · cited 1×
“However, a subsequent 3-arm study comparing MBSR training to both active control (supportive group with relaxation training) and wait list group failed to show any benefit [111].”
BackgroundArnold, L. M., Russell, I. J., Diri, E. W., Duan, W. R., Young, J. P., Sharma, U., Martin, S. A., Barrett, J. A., & Haig, G. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2008.03.013 · Cited by 277
BERNARDY, K., FÜBER, N., KÖLLNER, V., & HÄUSER, W. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.100104 · Cited by 266
Arnold, L. M., Hess, E. V., Hudson, J. I., Welge, J. A., Berno, S. E., & Keck, P. E. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01089-0 · Cited by 261 · cited 1×
“However, the results from RCTs were marginal for improving pain, sleep and mood in FMS patients [89, 90], even with a flexible dose [91].”
A Double-blind Placebo Controlled Trial of Fluoxetine in Fibromyalgia
Wolfe, F., Cathey, M. A., & Hawley, D. J. (1994) · Scandinavian Journal of Rheumatology · doi:10.3109/03009749409103725 · Cited by 252
Acceptance and commitment therapy for fibromyalgia: A randomized controlled trial.
Wicksell, R. K., Kemani, M., Jensen, K., Kosek, E., Kadetoff, D., Sorjonen, K., Ingvar, M., & Olsson, G. L. (2013) · European Journal of Pain · doi:10.1002/j.1532-2149.2012.00224.x · Cited by 244 · cited 1×
“, maladaptive cognition, mood, quality of life; QOL) [113–115] although the effects on the primary FMS symptoms may be limited.”
BackgroundHäuser, W., Bernardy, K., Üçeyler, N., & Sommer, C. (2009) · Pain · doi:10.1016/j.pain.2009.05.014 · Cited by 243
Biology and therapy of fibromyalgia. Stress, the stress response system, and fibromyalgia
Martinez-Lavin, M. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2146 · Cited by 234 · cited 1×
“Overall, these studies suggest the presence of hyperactive sympathetic activity with hyporeactive response to stress [37–40].”
BackgroundAlmirall, D., Compton, S. N., Gunlicks‐Stoessel, M., Duan, N., & Murphy, S. A. (2012) · Statistics in Medicine · doi:10.1002/sim.4512 · Cited by 223 · cited 1×
“Similarly, the sequential multiple assignment randomization trials (SMART) [121] approach, in which patients undergo multiple randomization to sequential treatments, may provide adaptive analyses of efficacy at the individual patient level that could help establish the most effective clinical algorithm.”
BackgroundComparative Efficacy and Harms of Duloxetine, Milnacipran, and Pregabalin in Fibromyalgia Syndrome
Häuser, W., Petzke, F., & Sommer, C. (2010) · The Journal of Pain · doi:10.1016/j.jpain.2010.01.002 · Cited by 216 · cited 1×
“A comparative evaluation of pregabalin, milnacipran and duloxetine [72] showed similar efficacy of the three drugs with regard to pain reduction.”
BackgroundAdler, G. K., Kinsley, B. T., Hurwitz, S., Mossey, C. J., & Goldenberg, D. L. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00074-1 · Cited by 200 · cited 1×
“associated with altered basal catecholamine levels, independent of depression [33, 34], as well as abnormal reactivity of the HPA, such as abnormal adrenocorticotropic hormone (ACTH) levels, hypoglycemia and blunted cortisol response [35, 36].”
BackgroundInaccuracy in the diagnosis of fibromyalgia syndrome: analysis of referrals
Fitzcharles, M.-A. (2003) · Rheumatology · doi:10.1093/rheumatology/keg075 · Cited by 153 · cited 1×
“Unfortunately, the clinical utility of the ACR criteria is quite limited [15] and the concordance between the ACR criteria and clinical diagnosis is rather poor [16].”
BackgroundBernardy, K., Füber, N., Klose, P., & Häuser, W. (2011) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-12-133 · Cited by 95 · cited 1×
“Generally, inconsistent and modest effects have been reported with hypnosis and biofeedback [108, 109].”
BackgroundAlda, M., Luciano, J. V., Andrés, E., Serrano-Blanco, A., Rodero, B., del Hoyo, Y. L., Roca, M., Moreno, S., Magallón, R., & García-Campayo, J. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3496 · Cited by 77 · cited 1×
“, maladaptive cognition, mood, quality of life; QOL) [113–115] although the effects on the primary FMS symptoms may be limited.”
BackgroundLong-Term Safety, Tolerability, and Efficacy of Duloxetine in the Treatment of Fibromyalgia
Mease, P. J., Russell, I. J., Kajdasz, D. K., Wiltse, C. G., Detke, M. J., Wohlreich, M. M., Walker, D. J., & Chappell, A. S. (2010) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.11.001 · Cited by 54 · cited 1×
“An extension trial [65] of up to 1 year showed comparable tolerability and”
Background
Cited by
Diagnostic Criteria for Fibromyalgia: Critical Review and Future Perspectives
Galvez-Sánchez, C. M., & Reyes del Paso, G. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041219 · Cited by 241
Grayston, R., Czanner, G., Elhadd, K., Goebel, A., Frank, B., Üçeyler, N., Malik, R. A., & Alam, U. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2018.08.003 · Cited by 213
Murai, N., Kondo, Y., Akuzawa, S., Mihara, T., Shiraishi, N., Kakimoto, S., & Matsumoto, M. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172750 · Cited by 34
Martínez, M. P., Sánchez, A. I., Prados, G., Lami, M. J., Villar, B., & Miró, E. (2021) · The Spanish Journal of Psychology · doi:10.1017/sjp.2021.30 · Cited by 24
Moshrif, A., Mosallam, A., Abu-Zaid, M. H., & Gouda, W. (2023) · Journal of Pain Research · doi:10.2147/jpr.s381314 · Cited by 12
“In the same context, the subjective nature of the disease and the absence of validated diagnostic tests negatively impact its management and lead to more delayed diagnosis (DD) with more socioeconomic impairment.(10) However, there is still a lack of studies about the effect of DD on the disease status and patients’ s…”
Background
Metadata
- Authors
- Okifuji, A., & Hare, B. D.
- Venue
- Pain and Therapy
- Published
- 2013-09-21
- Volume
- 2
- Issue
- 2
- Pages
- 87-104
- ISSN
- 2193-651X (ISSN-L)
- 2193-8237
- OpenAlex
- W2072075553
- Cited by
- 49
- References
- 30
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.